CoChat

Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy

Open access
Allen, Wendy L., Dunne, Philip D., McDade, Simon, Scanlon, Enya, Loughrey, Maurice, Coleman, Helen G., McCann, Christopher, McLaughlin, Kristy, Nemeth, Zsuzsanna, Syed, Najeeb Ashraf, Jithesh, Puthen Veettil, Arthur, Ken, Wilson, Richard, Coyle, Vicky M., McArt, Darragh, Murray, Graeme I., Samuel, Leslie, Nuciforo, Paolo, Jimenez, Jose, Argiles, Guillem, Dienstmann, Rodrigo, Tabernero, Josef, Picariello, Lucia, Messerini, Luca, Nobili, Stefania, Mini, Enrico, Sheahan, Kieran, Ryan, Elizabeth, Johnston, Patrick G., Van Schaeybroeck, Sandra, Lawler, Mark, Longley, Daniel B. · 2018 · JCO Precision Oncology
Cited by 71

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Transcriptomic profiling of colorectal cancer (CRC) has led to the identification of four consensus molecular subtypes (CMS1 to 4) that have prognostic value in stage II and III disease. More recently, the Colorectal Cancer Intrinsic Subtypes (CRIS) classification system has helped to define the biology specific to the epithelial component of colorectal tumors; however, the clinical value of these classification systems in the prediction of response to standard-of-care adjuvant chemotherapy remains unknown. Patients and Methods: Using samples from four European sites, we assembled a novel cohort of patients with stage II and III CRC (n = 156 samples) and performed transcriptomic profiling and targeted sequencing and generated a tissue microarray to enable integrated multiomics analyses. We also accessed data from two published cohorts of patients with stage II and III CRC: GSE39582 and GSE14333 (n = 479 and n = 185 samples, respectively). Results: The epithelial-rich CMS2 subtype of CRC benefitted significantly from treatment with adjuvant chemotherapy in both stage II and III disease ( P = .02 and P < .001, respectively), whereas the CMS3 subtype significantly benefitted in stage III only ( P = .001). After CRIS substratification of CMS2, we observed that only the CRIS-C subtype significantly benefitted from treatment with adjuvant chemotherapy in stage II and III disease ( P = .0081 and P < .001, respectively), whereas the CRIS-D subtype significantly benefitted in stage III only ( P = .0034). We also observed that CRIS-C patients with low levels of CD8+ tumor-infiltrating lymphocytes were most at risk for relapse in both stage II and III disease (log-rank P = .0031; hazard ratio, 12.18 [95% CI, 1.51 to 98.58]). Conclusion: Patient stratification using a combination of transcriptional subtyping and CD8 immunohistochemistry analyses is capable of identifying patients with poor prognostic stage II and III disease who benefit from adjuvant standard-of-care chemotherapy. These findings are particularly relevant for patients with stage II disease, where the overall benefit of adjuvant chemotherapy is marginal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/po.17.00241

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 71

Metadata

Authors
Allen, W. L., Dunne, P. D., McDade, S., Scanlon, E., Loughrey, M., Coleman, H. G., McCann, C., McLaughlin, K., Nemeth, Z., Syed, N. A., Jithesh, P. V., Arthur, K., Wilson, R., Coyle, V. M., McArt, D., Murray, G. I., Samuel, L., Nuciforo, P., Jimenez, J., Argiles, G., Dienstmann, R., Tabernero, J., Picariello, L., Messerini, L., Nobili, S., Mini, E., Sheahan, K., Ryan, E., Johnston, P. G., Van Schaeybroeck, S., Lawler, M., & Longley, D. B.
Venue
JCO Precision Oncology
Published
2018-11
Volume
2018
Issue
2
Pages
1-15
ISSN
2473-4284 (ISSN-L)
OpenAlex
W2808042645
Cited by
71
References
5
FWCI
3.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. https://app.cochat.ai/papers/10.1200/po.17.00241
The paper
Allen, W. L., Dunne, P. D., McDade, S., Scanlon, E., Loughrey, M., Coleman, H. G., McCann, C., McLaughlin, K., Nemeth, Z., Syed, N. A., Jithesh, P. V., Arthur, K., Wilson, R., Coyle, V. M., McArt, D., Murray, G. I., Samuel, L., Nuciforo, P., Jimenez, J., . . . Longley, D. B. (2018). Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology. https://doi.org/10.1200/po.17.00241

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.